Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines administered in the U.S. in ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...